STOCK TITAN

Vanguard (COEP) discloses 5.57% holding; Total Stock Market Fund holds 4.09%

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Coeptis Therapeutics Holdings Inc reports institutional ownership disclosures. Vanguard Capital Management reports beneficial ownership of 346,975 shares of Common Stock, representing 5.57% of the class. Vanguard Total Stock Market Index Fund Investor Shares holds 254,749 shares (4.09%). The filing lists voting and dispositive powers and provides Vanguard's Malvern, PA office address.

Positive

  • None.

Negative

  • None.

Insights

Vanguard reports just-above-5% stake in Coeptis, a typical 13G institutional disclosure.

The filing shows Vanguard Capital Management beneficially owns 346,975 shares (5.57%), with sole dispositive power over that position and sole voting power over 26,244 shares. This is a passive/ownership disclosure under Schedule 13G.

Key dependencies include fund-level holdings and any future amendments if the stake changes above passive thresholds; subsequent 13D/13G amendments will update ownership levels.

Schedule 13G format and footnote disclosures align with institutional reporting practices.

The filing includes the SEC Release citation and clarifies affiliates and funds through which Vanguard exercises dispositive power. It identifies the reporting persons and provides signatures dated 05/04/2026.

Material changes to ownership or intent would require amended filings; timing for any amendment is governed by Schedule 13G rules.

Vanguard beneficial ownership 346,975 shares Amount beneficially owned reported on Schedule 13G
Percent of class (Vanguard) 5.57% Percent of common stock reported by Vanguard Capital Management
Vanguard Total Stock Market Fund holdings 254,749 shares Holdings by Vanguard Total Stock Market Index Fund Investor Shares
Percent of class (Total Stock Market Fund) 4.09% Percent of common stock for the Total Stock Market Fund
Sole voting power 26,244 shares Shares for which Vanguard reports sole power to vote
Signature date 05/04/2026 Date of filing signatures
beneficially owned regulatory
"reflects the securities beneficially owned, or deemed to be beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Schedule 13G regulatory
"Item 1. (a) Name of issuer: Coeptis Therapeutics Holdings Inc"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
sole dispositive power regulatory
"Sole Dispositive Power 346,975.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
SEC Release No. 34-39538 regulatory
"In accordance with SEC Release No. 34-39538 (January 12, 1998)"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What stake does Vanguard report in Coeptis Therapeutics (COEP)?

Vanguard Capital Management reports beneficial ownership of 346,975 shares, equal to 5.57% of Coeptis Therapeutics' common stock. The Vanguard Total Stock Market Index Fund Investor Shares holds 254,749 shares (4.09%).

Who filed the Schedule 13G for COEP on behalf of Vanguard?

The filing was made by Vanguard Capital Management and includes holdings managed through affiliated funds. The signatory is Ashley Grim, Head of Global Fund Administration, dated 05/04/2026.

What voting and dispositive powers does Vanguard report for COEP shares?

Vanguard reports sole voting power for 26,244 shares and sole dispositive power for 346,975 shares. Shared voting and dispositive powers are reported as 0.

Does this Schedule 13G indicate Vanguard intends active control over Coeptis?

No. The filing is a passive ownership disclosure under Schedule 13G and does not state any intent to exert control. It lists beneficial ownership and the exercise of dispositive power through Vanguard affiliates.

Where is Vanguard's principal office listed in the COEP filing?

The filing lists Vanguard's principal business office as 100 Vanguard Blvd., Malvern, PA 19355. Coeptis' principal executive office is listed as 105 Bradford Road, Suite 420, Wexford, PA 15090.





19207A207

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd. This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power. This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release.


SCHEDULE 13G





SCHEDULE 13G



Vanguard Capital Management
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:05/04/2026
Vanguard Total Stock Market Index Fund Investor Shares
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:05/04/2026